Skip to content

US · ARTL · BIOTECHNOLOGY

Artelo Biosciences, Inc. (ARTL) intrinsic value and stock valuation

$1.39as of 2026-11-21 · Mkt cap 2.62M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Artelo Biosciences, Inc. DCF and intrinsic value

InvestorsCraft values ARTL with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from ARTL’s statements →

Artelo Biosciences, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Solana Beach, CA 92075 artelobio.com

How the business is doing

Fiscal 2014–2025, USD

Revenue
$0.00
20142025
Net income
-$-12.88M
20142025
Free cash flow
-$-8.52M
20142025
Total equity
-$-1.27M
20142025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2014–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-11.4M-$-10.11M-$-9.93M-$-10.29M-$-7.44M
Net income-$-12.88M-$-9.83M-$-9.29M-$-10.08M-$-7.44M
EPSd-$-5.46M-$-1.02M-$-1.05M-$-7.1M-$-12M
Operating cash flow-$-8.52M-$-8.35M-$-8.21M-$-8.01M-$-6.14M
Capital expenditure$0.00$0.00$0.00$0.00$0.00
Free cash flow-$-8.52M-$-8.35M-$-8.21M-$-8.01M-$-6.14M
Total assets$2.8M$4.7M$13M$20.4M$12.6M
Total debt$680K$100K$20K$60K$100K
Net debt$80K-$-2.23M-$-2.79M-$-6.83M-$-6.53M
Total equity-$-1.27M$2.86M$11.8M$19.4M$12M
Cash and short-term investments$600K$2.34M$10.4M$17.5M$10.1M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$0.00$0.00$0.00$0.00$0.00
Gross profit$0.00$0.00$0.00$0.00$0.00
Research and development expenses$5.42M$5.99M$5.7M$4.32M$2.84M
Selling, general and administrative expenses$5.98M$4.12M$4.23M$5.96M$4.6M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$11.4M$10.1M$9.93M$10.3M$7.44M
Cost and expenses$11.4M$10.1M$9.93M$10.3M$7.44M
Interest income$0.00$0.00$0.00$0.00$0.00
Interest expense$190K$0.00$0.00$10K$0.00
Depreciation and amortization$150K$0.00$0.00$0.00$0.00
Ebitda-$-12.54M-$-9.83M-$-9.29M-$-10.08M-$-7.44M
Operating income-$-11.4M-$-10.11M-$-9.93M-$-10.29M-$-7.44M
Total other income/expenses, net-$-1.48M$280K$640K$200K$0.00
Income before tax-$-12.88M-$-9.83M-$-9.29M-$-10.08M-$-7.44M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-12.88M-$-9.83M-$-9.29M-$-10.08M-$-7.44M
Weighted average shares outstanding$2.36M$9.67M$8.88M$1.42M$620K
Weighted average diluted shares outstanding$2.36M$9.67M$8.88M$1.42M$620K
Balance sheet
20252024202320222021
Cash and short-term investments$600K$2.34M$10.4M$17.5M$10.1M
Net receivables$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$690K$2.56M$11M$18.3M$10.3M
Property, plant and equipment, net$60K$100K$20K$60K$90K
Goodwill and intangible assets$2.04M$2.04M$2.04M$2.04M$2.04M
Long-term investments$0.00$0.00$0.00-$-1.5M$0.00
Total non-current assets$2.11M$2.14M$2.06M$2.1M$2.32M
Total assets$2.8M$4.7M$13M$20.4M$12.6M
Accounts payable$3.04M$1.68M$1.24M$910K$490K
Short-term debt$650K$40K$20K$40K$30K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$4.04M$1.77M$1.29M$1M$530K
Long-term debt$30K$70K$0.00$20K$70K
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$30K$70K$0.00$20K$70K
Capital lease obligations$70K$100K$20K$0.00$0.00
Total liabilities$4.07M$1.84M$1.29M$1.02M$590K
Common stock$0.00$0.00$0.00$0.00$30K
Retained earnings-$-63.02M-$-50.14M-$-40.31M-$-31.02M-$-16.9M
Accumulated other comprehensive income (loss)-$-270K-$-200K-$-200K-$-250K$20K
Total equity-$-1.27M$2.86M$11.8M$19.4M$12M
Total investments$0.00$0.00$7.61M$9.15M$3.44M
Total debt$680K$100K$20K$60K$100K
Net debt$80K-$-2.23M-$-2.79M-$-6.83M-$-6.53M
Cash flow statement
20252024202320222021
Net income-$-12.88M-$-9.83M-$-9.29M-$-10.08M-$-7.44M
Depreciation and amortization$150K$0.00$0.00$0.00$0.00
Stock-based compensation$1.14M$820K$1.02M$2.46M$1.53M
Change in working capital$1.75M$940K$700K-$-170K-$-240K
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$1.59M$480K$270K$20K-$0.00
Net cash provided by operating activities-$-8.52M-$-8.35M-$-8.21M-$-8.01M-$-6.14M
Investments in property, plant and equipment$0.00$0.00$0.00$0.00$0.00
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-60K$7.77M$3.51M$2.96M-$-3.44M
Common stock issued$6.28M$110K$570K$0.00$8.1M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$6.87M$110K$570K$0.00$14.1M
Net change in cash-$-1.74M-$-480K-$-4.07M-$-5.27M$4.49M
Cash at end of period$600K$2.34M$2.81M$6.89M$6.63M
Operating cash flow-$-8.52M-$-8.35M-$-8.21M-$-8.01M-$-6.14M
Capital expenditure$0.00$0.00$0.00$0.00$0.00
Free cash flow-$-8.52M-$-8.35M-$-8.21M-$-8.01M-$-6.14M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Artelo Biosciences, Inc.

        Artelo Biosciences, Inc. functions as a clinical-stage biopharmaceutical enterprise dedicated to discovering and advancing therapies that modulate the endocannabinoid system. The company's robust developmental portfolio encompasses several promising candidates: ART27.13, a synthetic G protein-coupled receptor agonist currently undergoing Phase 1b/2a clinical investigation for cancer-related anorexia; ART12.11, a synthetic cannabidiol cocrystal being explored for inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor with potential applications in prostate and breast cancer treatment, as well as PTSD. Further extending its research efforts, Artelo has established a collaborative partnership with Trinity College Dublin to probe ART27.13's efficacy in addressing cancer cachexia. Established in 2011, the entity initially operated under the name Reactive Medical, Inc. before rebranding as Artelo Biosciences, Inc. in April 2017. Its corporate headquarters are situated in Solana Beach, California.

        CEO
        Gregory D. Gorgas
        Employees
        7
        Beta
        -0.07

        Explore

        Frequently asked questions

        What is the intrinsic value of Artelo Biosciences, Inc. (ARTL)?

        InvestorsCraft does not currently publish an intrinsic value for ARTL. How the IC value is calculated.

        Is ARTL undervalued?

        InvestorsCraft does not publish an undervaluation signal for ARTL at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.